Fierce Biotech1 min read
saveMerck axes $2.7B BTK inhibitor program after seeing phase 3 data
Merck & Co. has stopped a trio of phase 3 blood cancer trials after one study suggested the benefits of the BTK inhibitor may fail to outweigh the risks, bringing the curtain down on a program stemming from a $2.7 billion takeover.
comments(0)
5-min edit window · permanent after that